Advertise on podcast: Addiction Medicine: Beyond the Abstract

In today's Episode Rewind, we're revisiting our talk with Dr. Pouya Azar talking about his article Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative. He discusses the potential benefits of transitioning patients with opioid use disorder from traditional to extended-release or long-acting buprenorphine within 7 days or 24 hours, respectively, of treatment, as well as challenges and future questions that arose from his narrative review. Pouya Azar, MD, FRCPC, DABAM, is a clinician-scientist in addiction psychiatry and pain medicine based in Vancouver, British Columbia, Canada. He serves as co-medical manager of the Complex Pain and Addiction Service (CPAS) at Vancouver Coastal Health, a consult service providing management of pain, mental health disorders, and substance use disorders across Vancouver General Hospital, the University of British Columbia (UBC) Hospital, and GF Strong Rehabilitation Centre. He is also an assistant professor (tenure-track) in the UBC Department of Psychiatry, research scientist co-lead of the Substance Use Disorder Clinical Research Unit at the BC Centre for Excellence in HIV/AIDS, and a physician at the Vancouver General Hospital Transitional Pain Clinic. Dr. Azar’s clinical and translational research focuses on developing novel opioid agonist treatment initiation and withdrawal management protocols, medical devices, digital health apps, and prevention programs to improve patient outcomes. - Article Link: Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative

In today's episode, Dr. Mark McGovern and Dr. Berkeley Franz stop by the show to discuss their latest article Medication Approaches for Patients With Opioid Use Disorders: Differences Between Primary Care Clinics and Specialty Addiction Treatment Programs, featured in the July/August issue of the Journal of Addiction Medicine.   Article Link: Medication Approaches for Patients With Opioid Use Disorders: Differences Between Primary Care Clinics and Specialty Addiction Treatment Programs

In this episode, infectious diseases physician Dr. Liz Novick stops by to discuss her recent study Clinical and Demographic Characteristics of Hospitalized Patients With Xylazine-related Wounds featured in the May/June issue of the Journal of Addiction Medicine.   Article Link: Clinical and Demographic Characteristics of Hospitalized Patients With Xylazine-related Wounds

In today's episode, Drs. Nicole Malette and Paxton Bach join the show to discuss their new article Approaches for Managing Benzodiazepine Dependence Arising From Use of the Adulterated Opioid Supply: A Delphi Technique featured in the July/August issue of the Journal of Addiction Medicine.   Article Link: Approaches for Managing Benzodiazepine Dependence Arising From Use of the Adulterated Opioid Supply: A Delphi Technique

In this episode, Dr. Jeanmarie Perrone sits down to discuss her new article The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine featured in the May/June issue of the Journal of Addiction Medicine. Jeanmarie Perrone, MD is a Professor in the Department of Emergency Medicine, the Director of Addiction Toxicology, and the founding Director of the Penn Center for Addiction Medicine and Policy, all at the University of Pennsylvania. Dr. Perrone has led multiple initiatives through the emergency department for the initiation of treatment for substance use disorders.  Dr. Perrone has been recognized with several awards for education and mentorship and is board certified in emergency medicine, medical toxicology and addiction medicine.  Article Link: The Shifting Landscape of a Fentanyl Adulterant: Moving From Xylazine to Medetomidine

In this episode of Beyond The Abstract, Dr. Joao De Aquino joins the show to talk about his new article The Role of Childhood Trauma in Chronic Pain and Substance Use Among Individuals Receiving Methadone Treatment for Opioid Use Disorder featured in the May/June issue of the Journal of Addiction Medicine.   Article Link: The Role of Childhood Trauma in Chronic Pain and Substance Use Among Individuals Receiving Methadone Treatment for Opioid Use Disorder

In this special episode, Drs. Carla Marienfeld, Marcela Smid, Tanner Wright, and Ljuba Mirsky, discuss the emerging concept of fetal fentanyl syndrome.   Prenatal Fentanyl Exposure Association With... : Journal of Addiction Medicine Authors Whitley W, Cockerham C, Mirsky E, O’Brien J, Parilla B, Hawk G.   Descriptive Exploration of Features Among Infants... : Journal of Addiction Medicine  Authors: Davidson A, Benninger KL, Henninger ML, et al.   Related Article: Fetal Fentanyl Syndrome: An Opportunity to... : Journal of Addiction Medicine  Authors Hernandez-Diaz S, Huybrechts KF.

In this episode of Beyond The Abstract, Dr. Kathleen Adams stops by to talk about her new article Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review featured in the May/June issue of the Journal of Addiction Medicine.   Article Link: Low-dose Buprenorphine Initiation in Pregnancy: A Systematic Review

In this episode of Beyond The Abstract, Dr. Manish Jha stops by to talk about his new article Craving, Impulsivity, and Subsequent Methamphetamine Use With Naltrexone-Bupropion Versus Placebo: Findings From a Randomized Clinical Trial featured in the March/April issue of the Journal of Addiction Medicine.   Article Link: Craving, Impulsivity, and Subsequent Methamphetamine Use With Naltrexone-Bupropion Versus Placebo: Findings From a Randomized Clinical Trial

In this episode of Beyond The Abstract, Dr. Phil Durney and Dr. Kory London stop by the show to discuss their latest article featured in the current March/April issue of the Journal of Addiction Medicine titled Severe Fentanyl Withdrawal Associated With Medetomidine Adulteration: A Multicenter Study From Philadelphia, PA.   They discuss what medetomidine is, how it functions, and how its emergence in the fentanyl supply is impacting the opioid crisis in the US, as well as clinical management of medetomidine exposure and withdrawal in hospital and outpatient settings.   Article Link: Severe Fentanyl Withdrawal Associated With Medetomidine Adulteration: A Multicenter Study From Philadelphia, PA

In this episode, Dr. Nabila El-Bassel stops by the show to discuss her new research article Artificial Intelligence and Stigma in Addiction Research: Insights From the HEALing Communities Study Coalition Meetings, featured in the March/April 2026 issue of the Journal of Addiction Medicine.   Article Link: Addiction Research: Insights From the HEALing Communities Study Coalition Meetings

In this episode, Dr. Jasmine Barnes and Dr. Margaret Lowenstein sit down to discuss their new article Characterization of a Young Adult Sample Accessing Buprenorphine Via Telehealth in Philadelphia, PA featured in the January/February 2026 issue of the Journal of Addiction Medicine.   Article Link: Characterization of a Young Adult Sample Accessing Buprenorphine Via Telehealth in Philadelphia, PA

In today's Episode Rewind we're revisiting our interview with Dr. Marcela Smid, live at the 56th Annual ASAM Conference in Denver. Dr. Smid sits down to discuss article submissions and peer review, as well as demystifying the scientific publishing process for new authors.   Learn more about this year's upcoming conference in San Diego, CA > https://bit.ly/3OTOx79

In this episode of Beyond The Abstract, Dr. Matthew Sloan sits down to discuss findings from his recent article Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine featured in the November/December issue of the Journal of Addiction Medicine. Join us as Dr. Sloan shares insights into his study investigating the feasibility of delivering symptom-triggered alcohol withdrawal management over telemedicine.   Dr. Matthew Sloan is a clinician scientist at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada. He specializes in the treatment of substance use disorders and their psychiatric comorbidities. He completed medical school and psychiatry residency at McGill University followed by a postdoctoral fellowship in human psychopharmacology at the National Institutes of Health and an addiction psychiatry fellowship at Yale University. Dr. Sloan's primary research interests are developing innovative new treatments for substance use disorders and exploring determinants of psychopharmacological response to drugs of misuse. He has obtained competitive research funding from the Canadian Institutes of Health Research, Health Canada, and the Centre for Addiction and Mental Health Discovery Fund and has received scientific prizes from the American Academy of Addiction Psychiatry and the National Institute on Alcohol Abuse and Alcoholism.   Article Link: Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine

In this episode, Dr. Nicolas Garel joins the podcast to discuss findings from his new article in the September/October issue of the Journal of Addiction Medicine titled Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study. Dr. Nicolas Garel is a psychiatrist and clinician-scientist at the Centre Hospitalier de l’Université de Montréal (CHUM). He is an assistant professor in the Department of Psychiatry at the Université de Montréal and adjunct professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. Dr. Garel completed his medical degree at the Université de Montréal, followed by his psychiatry residency and clinician-scientist fellowship at McGill University, and later pursued advanced training in research and addiction medicine at Stanford University. His research program focuses on innovative interventions for treatment-resistant mood disorders and substance use disorders.   Article Link: Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study